|Treatments:||Chemotherapy||Hospital:||Laikon General Hospital|
Patients: This phase II study involved 41 patients with FIGO III/IV ovarian cancer. The median age was 60 years. 19 patients received optimal debulking surgury and 17 patients received suboptimal debulking prior to entry in the study.
Treatment: The treatment consisted of chemotherapy: paclitaxel plus carboplatin followed by carboplatin and liposomal doxorubicin.
Toxicity: Grade 3 and 4 toxicities included neutorpenia (including with fever), thrombocytopenia, nausea-vomiting, fatigue, and neurotoxicity.
Results: The median survival has not yet been reached, but the probability of 2 year survival was reported as 67%.
Correspondence: Prof. Aristides Polyzos